Clinical trial · Interventional
Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes
Adjuvant Vaccination With Melanoma Antigen Pulsed Dendritic Cells (DCs) in Stage III Melanoma Patients
NCT01082198CI-TRIAL-00011891unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Vaccines made from dendritic cells and tumor antigen peptides or a person's tumor cells may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best way to give melanoma vaccine in treating patients with stage III melanoma after surgery to remove the lymph nodes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma (Skin) | Melanoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (7)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| adjuvant therapy | Procedure | — | UNRESOLVED |
| autologous melanoma lysate/KLH-pulsed autologous dendritic cell vaccine | Biological | — | UNRESOLVED |
| autologous melanoma lysate-pulsed autologous dendritic cell vaccine | Biological | — | UNRESOLVED |
| dendritic cell-idiotype-keyhole limpet hemocyanin vaccine | Biological | — | UNRESOLVED |
| flow cytometry | Other | — | UNRESOLVED |
| HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine | Biological | — | UNRESOLVED |
| HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine | Biological | — |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Immune response
- measure
- Disease-free survival
- measure
- Overall survival
- measure
- Adverse events
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of stage III melanoma * Has undergone therapeutic lymphadenectomy * More than 1 lymph node involvement or extracapsular extension of metastatic melanoma cells (stage N1b-N3 disease according to AJCC 2002) * HLA type A1 and/or A2 or A3 (if autologous tumor lysate is available) * No presence of distant metastases PATIENT CHARACTERISTICS: * No other malignancy * No evidence of lung, heart, liver, or renal failure or severe neurologic disorder * No autoimmune disease or atopic allergy * No HIV infection or presence of anti-HIV antibodies * No presence of hepatitis B surface antigen or antibodies against hepatitis C virus PRIOR CONCURRENT THERAPY: * See Disease Characteristics
References
Publications (0)
Data not yet available
No reference posted for this study.